Cargando…

A cost-effectiveness analysis of an in-hospital clinical pharmacist service

OBJECTIVE: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallerstedt, Susanna M, Bladh, Lina, Ramsberg, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253415/
https://www.ncbi.nlm.nih.gov/pubmed/22223840
http://dx.doi.org/10.1136/bmjopen-2011-000329
_version_ 1782220728082366464
author Wallerstedt, Susanna M
Bladh, Lina
Ramsberg, Joakim
author_facet Wallerstedt, Susanna M
Bladh, Lina
Ramsberg, Joakim
author_sort Wallerstedt, Susanna M
collection PubMed
description OBJECTIVE: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic model. DESIGN: A piggyback cost-effectiveness analysis from the healthcare perspective. SETTING: Two internal medicine wards at Sahlgrenska University Hospital, Göteborg, Sweden. PARTICIPANTS: Of 345 patients (61% women; median age: 82 years; 181 control and 164 intervention patients), 240 patients (62% women, 82 years; 124 control and 116 intervention patients) had EuroQol-5 dimensions (EQ-5D) utility scores at baseline and at 6-month follow-up. OUTCOME MEASURES: Costs during a 6-month follow-up period in all patients and incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) in patients with EQ-5D utility scores. Inpatient and outpatient care was extracted from the VEGA database. Drug costs were extracted from the Swedish Prescribed Drug Register. A probabilistic analysis was performed to characterise uncertainty in the cost-effectiveness model. RESULTS: No significant difference in costs between the randomisation groups was found; the mean total costs per individual±SD, intervention costs included, were €10 748±13 799 (intervention patients) and €10 344±14 728 (control patients) (p=0.79). For patients in the cost-effectiveness analysis, the corresponding costs were €10 912±13 999 and €9290±12 885. Intervention patients gained an additional 0.0051 QALYs (unadjusted) and 0.0035 QALYs (adjusted for baseline EQ-5D utility score). These figures result in an incremental cost-effectiveness ratio of €316 243 per unadjusted QALY and €463 371 per adjusted QALY. The probabilistic uncertainty analysis revealed that, at a willingness-to-pay of €50 000/QALY, the probability that the intervention was cost-effective was approximately 0.2. CONCLUSIONS: The present study reveals that an intervention designed like this one is probably not cost-effective. The study thus illustrates that the complexity of healthcare requires thorough health economics evaluations rather than simplistic interpretation of data.
format Online
Article
Text
id pubmed-3253415
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-32534152012-01-17 A cost-effectiveness analysis of an in-hospital clinical pharmacist service Wallerstedt, Susanna M Bladh, Lina Ramsberg, Joakim BMJ Open Pharmacology and Therapeutics OBJECTIVE: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic model. DESIGN: A piggyback cost-effectiveness analysis from the healthcare perspective. SETTING: Two internal medicine wards at Sahlgrenska University Hospital, Göteborg, Sweden. PARTICIPANTS: Of 345 patients (61% women; median age: 82 years; 181 control and 164 intervention patients), 240 patients (62% women, 82 years; 124 control and 116 intervention patients) had EuroQol-5 dimensions (EQ-5D) utility scores at baseline and at 6-month follow-up. OUTCOME MEASURES: Costs during a 6-month follow-up period in all patients and incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) in patients with EQ-5D utility scores. Inpatient and outpatient care was extracted from the VEGA database. Drug costs were extracted from the Swedish Prescribed Drug Register. A probabilistic analysis was performed to characterise uncertainty in the cost-effectiveness model. RESULTS: No significant difference in costs between the randomisation groups was found; the mean total costs per individual±SD, intervention costs included, were €10 748±13 799 (intervention patients) and €10 344±14 728 (control patients) (p=0.79). For patients in the cost-effectiveness analysis, the corresponding costs were €10 912±13 999 and €9290±12 885. Intervention patients gained an additional 0.0051 QALYs (unadjusted) and 0.0035 QALYs (adjusted for baseline EQ-5D utility score). These figures result in an incremental cost-effectiveness ratio of €316 243 per unadjusted QALY and €463 371 per adjusted QALY. The probabilistic uncertainty analysis revealed that, at a willingness-to-pay of €50 000/QALY, the probability that the intervention was cost-effective was approximately 0.2. CONCLUSIONS: The present study reveals that an intervention designed like this one is probably not cost-effective. The study thus illustrates that the complexity of healthcare requires thorough health economics evaluations rather than simplistic interpretation of data. BMJ Group 2012-01-05 /pmc/articles/PMC3253415/ /pubmed/22223840 http://dx.doi.org/10.1136/bmjopen-2011-000329 Text en © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Pharmacology and Therapeutics
Wallerstedt, Susanna M
Bladh, Lina
Ramsberg, Joakim
A cost-effectiveness analysis of an in-hospital clinical pharmacist service
title A cost-effectiveness analysis of an in-hospital clinical pharmacist service
title_full A cost-effectiveness analysis of an in-hospital clinical pharmacist service
title_fullStr A cost-effectiveness analysis of an in-hospital clinical pharmacist service
title_full_unstemmed A cost-effectiveness analysis of an in-hospital clinical pharmacist service
title_short A cost-effectiveness analysis of an in-hospital clinical pharmacist service
title_sort cost-effectiveness analysis of an in-hospital clinical pharmacist service
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253415/
https://www.ncbi.nlm.nih.gov/pubmed/22223840
http://dx.doi.org/10.1136/bmjopen-2011-000329
work_keys_str_mv AT wallerstedtsusannam acosteffectivenessanalysisofaninhospitalclinicalpharmacistservice
AT bladhlina acosteffectivenessanalysisofaninhospitalclinicalpharmacistservice
AT ramsbergjoakim acosteffectivenessanalysisofaninhospitalclinicalpharmacistservice
AT wallerstedtsusannam costeffectivenessanalysisofaninhospitalclinicalpharmacistservice
AT bladhlina costeffectivenessanalysisofaninhospitalclinicalpharmacistservice
AT ramsbergjoakim costeffectivenessanalysisofaninhospitalclinicalpharmacistservice